These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 34747194)
21. One-year outcome of cystoid macular degeneration in central serous chorioretinopathy. Kumar Sahoo N; Lupidi M; Goud A; Gangakhedkar S; Cardillo Piccolino F; Chhablani J Eur J Ophthalmol; 2022 Jul; 32(4):2347-2354. PubMed ID: 34615406 [TBL] [Abstract][Full Text] [Related]
22. Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization. Kamimura A; Miki A; Kishi M; Okuda M; Hayashida-Hirano M; Sakamoto M; Matsumiya W; Imai H; Kusuhara S; Nakamura M PLoS One; 2023; 18(5):e0284979. PubMed ID: 37130134 [TBL] [Abstract][Full Text] [Related]
24. Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study. Iovino C; Au A; Chhablani J; Parameswarappa DC; Rasheed MA; Cennamo G; Cennamo G; Montorio D; Ho AC; Xu D; Querques G; Borrelli E; Sacconi R; Pichi F; Woodstock E; Sadda SR; Corradetti G; Boon CJF; van Dijk EHC; Loewenstein A; Zur D; Yoshimi S; Freund KB; Peiretti E; Sarraf D Am J Ophthalmol; 2020 Sep; 217():104-113. PubMed ID: 32360342 [TBL] [Abstract][Full Text] [Related]
25. Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy. Park YJ; Kim YK; Park KH; Woo SJ Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):760-770. PubMed ID: 31877221 [TBL] [Abstract][Full Text] [Related]
27. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076 [TBL] [Abstract][Full Text] [Related]
28. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy. Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002 [TBL] [Abstract][Full Text] [Related]
29. Pattern electroretinography in patients with unilateral acute central serous chorioretinopathy. Doguizi S; Sekeroglu MA; Ozkoyuncu D; Yilmazbas P Clin Exp Optom; 2020 Sep; 103(5):656-662. PubMed ID: 31822040 [TBL] [Abstract][Full Text] [Related]
30. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183 [TBL] [Abstract][Full Text] [Related]
31. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Hayashida M; Miki A; Honda S; Nakamura M Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640 [TBL] [Abstract][Full Text] [Related]
32. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Arevalo JF; Espinoza JV Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811 [TBL] [Abstract][Full Text] [Related]
33. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data. Subhi Y; Bjerager J; Boon CJF; van Dijk EHC Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168 [TBL] [Abstract][Full Text] [Related]
34. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858 [TBL] [Abstract][Full Text] [Related]
35. Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report. Liu Y; Wang X; Zhu M; Xu G; Li L BMC Ophthalmol; 2019 Mar; 19(1):68. PubMed ID: 30849939 [TBL] [Abstract][Full Text] [Related]
36. Ganglion Cell Loss in the Course of Central Serous Chorioretinopathy. Gawęcki M; Grzybowski A Ophthalmol Ther; 2023 Feb; 12(1):517-533. PubMed ID: 36510030 [TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230 [TBL] [Abstract][Full Text] [Related]
38. Gender differences in central serous chorioretinopathy based on the new multimodal imaging classification. Sahoo NK; Ong J; Selvam A; Brown R; Avdalimov M; Kulkarni A; Hansraj S; Gujar R; Lupidi M; Zur D; Chhablani J Eye (Lond); 2024 Apr; 38(5):964-967. PubMed ID: 37925559 [TBL] [Abstract][Full Text] [Related]
39. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the outcomes of photodynamic therapy for central serous chorioretinopathy with or without subfoveal fibrin. Liang Z; Qu J; Huang L; Linghu D; Hu J; Jin E; Xu H; Li H; Tao Y; Xu X; Liu G; Li Y; Zhao M Eye (Lond); 2021 Feb; 35(2):418-424. PubMed ID: 32291401 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]